LAM Week


Welcome Message

Lymphangioleiomyomatosis (lim-FAN-jee-oh-ly-oh-myoh-ma-TOE-sis; LAM) is a rare lung disease that mostly affects women of childbearing age. It begins insidiously and advances to cause breathlessness first with physical activity, and later, even at rest. Thanks in part to research funded by the ATS and The LAM Foundation, much exciting progress has been made in figuring out the biologic mechanisms behind LAM, and developing specific therapy. Most people have never heard of LAM, much less know how to pronounce its full name, and many clinicians are in the dark. The ATS recognizes the need to disseminate information publically, especially to people with LAM, their families and health care providers. The ATS, its researchers, and health professionals must interface with patients and their families. The ATS is committed to its PAR partnership with The LAM Foundation to ensure that stakeholders see the enduring value of ongoing work and research related to LAM. The LAM Foundation is an outstanding source of information and support for patients, families and friends. Members of the ATS are international experts on LAM, and are involved in cutting edge research. Thanks to their efforts, there is the promise of improved treatment, and hopefully, an eventual cure for people with LAM.
Dona Upson, MD
Dona Upson, MD
Past Chair, Council of Chapter
Representatives (CCR)
American Thoracic Society
Mary Harbaugh, MD
Mary Harbaugh, PhD
Board Member
The LAM Foundation Member,
ATS Public Advisory Roundtable


ATS LAM Partner

The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical and patient communities by offering information, resources and a worldwide network of hope and support.